Kusajili – Clinical trials directory

Result of your search per sponsor: Jurgen Knobloch, MD

Woman and Man Max 99 years
Jurgen Knobloch, MD Update Il y a 4 ans

GMZ2-Aluminum Hydroxide Phase I, Tübingen This is a randomized, open, dose-selection Phase 1 study. The study aims to evaluate the safety and immunogenicity of 3 doses (10,30 & 100 micrograms) of the GMZ2 hybrid (GLURP and MSP3) b...

Country Germany
organs None
Specialty None

unknown

More information